Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

NCT07040943 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Refractory Malignant Solid Tumors
mRNA Vaccine
Interleukin

Interventions

BIOLOGICAL: IL-22BP

Sponsor

West China Hospital